The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
SPEVIGO is a novel, selective antibody infusion that blocks the activation of the interleukin-36 receptor, which is part of an immune system signaling pathway thought to be involved in the cause of GPP. The approval was based on a 12-week trial in which 53 patients with a GPP flare were treated with SPEVIGO or placebo. After one week, more patients treated with SPEVIGO showed no visible pustules than those treated with placebo (54 versus 6 percent).
The most common adverse reactions (≥5 percent) reported in patients taking SPEVIGO were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection.
“GPP flares can greatly impact a patient’s life and lead to serious, life-threatening complications,” Mark Lebwohl, M.D., lead investigator for the trial, said in a statement. “The approval of SPEVIGO is a turning point for dermatologists and clinicians.”
Approval of SPEVIGO was granted to Boehringer Ingelheim.
FDA Approval
Copyright © 2022 HealthDay. All rights reserved.
Citation:
FDA approves SPEVIGO for generalized pustular psoriasis flares (2022, September 7)
retrieved 11 September 2022
from https://medicalxpress.com/news/2022-09-fda-spevigo-pustular-psoriasis-flares.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Source link
